Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112609 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Junjun Liu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 2002…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Neoplasms, T-Lymphocytes, Immunotherapy. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 167 Literaturangaben. Gefördert von: National Key New Drug Creation and Manufacturing Program, Ministry of Science and Technology, National Major Science and Technology Projects of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
T-cell-engaging bispecific antibody (TCB) therapies have emerged as a promising immunotherapeutic approach, effectively redirecting effector T cells to selectively eliminate tumor cells. The therapeutic potential of TCBs has been well recognized, particularly with the approval of multiple TCBs in recent years for the treatment of hematologic malignancies as well as some solid tumors. However, TCBs encounter multiple challenges in treating solid tumors, such as on-target off-tumor toxicity, cytokine release syndrome (CRS), and T cell dysfunction within the immunosuppressive tumor microenvironment, all of which may impact their therapeutic efficacy. In this review, we summarize clinical data on TCBs for solid tumor treatment, highlight the challenges faced, and discuss potential solutions based on emerging strategies from current clinical and preclinical research. These solutions include TCB structural optimization, target selection, and combination strategies. This comprehensive analysis aims to guide the development of TCBs from design to clinical application, addressing the evolving landscape of cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.
- Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China; Jecho Laboratories, Inc., Frederick, MD 21704, USA. Electro…
Förderung
- National Key New Drug Creation and Manufacturing Program, Ministry of Science and Technology
- National Major Science and Technology Projects of China
- National Natural Science Foundation of China
Zitieren
APA
Liu, J., & Zhu, J. (2024). Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112609
Vancouver
Liu J, Zhu J. Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112609
BibTeX
@article{Liu2024,
author = {Liu, Junjun and Zhu, Jianwei},
title = {Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112609}
}
EUVIMED